Compare TG Therapeutics Inc (TGTX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 6.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| TGTX | VCSH | |
|---|---|---|
Market Cap | $8.16B | $51.90B |
Volume | 1,735,121 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $59.06 | $80.20 |
52-Week Low | $26.94 | $77.03 |
Typical Hold Time | 16 Days | 52 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VCSH trades at $77.285 with minimal daily movement (+0.02%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains a competitive 4.5% dividend yield with a low 0.03% expense ratio, though recent analysis suggests credit spreads appear tight. Recent institutional activity shows mixed positioning with both stake increases and reductions reported.
The short-term corporate bond ETF faces headwinds from potential rate environment shifts while offering higher yields than treasury alternatives. Limited price appreciation potential exists given current technical positioning and market expectations of sustained rates, making it suitable for income-focused investors comfortable with corporate credit risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
